US Pharma MarketingCMS’s new GLP-1 Bridge program expands Medicare access to obesity drugs but raises concerns about cost, supply and implementation challenges. Toggle Search Close navigation News Health Tech BioPharma Devices & Diagnostics Consumer / Employer Contributors MedCity Influencers Events Bullseye INVEST Digital Health Podcasts Research Spotlight Payer Challenges and Opportunities Newsletters Newsletter Signup Send Tips Webinars eBooks Twitter Facebook TikTok YouTube LinkedIn RSS Subscribe via email Search for: Search Policy Does CMS Know What It Is Doing With Its GLP-1 Obesity Coverage Pilot? CMS’s new GLP-1 Bridge program expands Medicare access to obesity drugs but raises concerns about cost, supply and…
CMS’s new GLP-1 Bridge program expands Medicare access to obesity drugs but raises concerns about cost, supply and implementation challenges.
The post Does CMS Know What It Is Doing With Its GLP-1 Obesity Coverage Pilot? appeared first on MedCity News.
Source: MedCity News